R&D
Successfully Completed Phase I Single Dose Study for GXV-001

GEXVal Inc.January 10, 2023 GEXVal Inc. is conducting a Phase I study for GXV-001, a new drug candidate, throu […]

Read more
External announcement
GEXVal Gave Presentation at KIRIN

GEXVal Inc.December 27, 2022 Juran Kato, PhD, president and CEO of GEXVal ., was invited by Kirin Holdings Com […]

Read more
Information
Season’s Greetings

For further information, please contact us: info@gexval.com

Read more
External announcement
GEXVal CEO Won a Prize Outstanding Leadership Awards at health2.0 CONFERENCE

  GEXVal Inc.December 16,2022 Juran Kato, PhD, president and CEO of GEXVal ., received an Outstanding Leadersh […]

Read more
External announcement
GEXVal Gives a Presentation at "Let's Talk with VCs" Series Organized by Link-J

GEXVal Inc.November 25, 2022 Juran Kato, PhD, founder, president and CEO of GEXVal ., will give a presentation […]

Read more